Running a first-in-human study outside the US can offer faster start-up, lower costs and access to experienced phase 1 units, and some countries offer incentives that make the economics attractive. The trade-offs are real, though: the data must be acceptable to FDA later, the program needs a clear plan for moving to a US IND, and operating in another regulatory system adds legal, logistical and oversight work that small sponsors often underestimate. The right answer depends on the program, not on the trend.
Why do emerging sponsors look abroad for first-in-human?
Speed is the most common reason. In some countries, the regulatory pathway for early-phase studies is streamlined, and start-up can move quickly once ethics approval is in hand. Costs can be lower. Experienced phase 1 units are available. And some jurisdictions offer financial incentives. Australia, for example, combines a notification-based pathway for many trials, the Clinical Trial Notification scheme, with an R&D tax incentive that can return part of eligible spend to qualifying companies, subject to its rules.
Will FDA accept the data?
FDA can accept data from foreign clinical studies not conducted under an IND, provided the studies are well designed and well conducted, follow good clinical practice, including review by an independent ethics committee and proper informed consent, and FDA can validate the data through an on-site inspection if needed. The regulation is 21 CFR 312.120. The practical lesson is simple: conduct the study to the standard you would need for a US submission, and document it accordingly.
What are the hidden costs?
Local sponsor requirements. Some countries require a local sponsor entity, which often means setting up a subsidiary.
Legal and insurance. Local clinical trial insurance, contracts and indemnities.
Drug supply. Import permits, labeling, depot logistics and GMP documentation.
Oversight. Time zones, travel and a sponsor team that must oversee work it cannot easily visit.
Translation and documentation. Depending on the country, translated materials and local formats.
Advisory fees. Local regulatory and tax advice to qualify for incentives correctly.
How do you plan the path back to a US IND?
Start with the end in mind. Consider a pre-IND interaction with FDA to discuss the foreign data and the planned US studies. Make sure nonclinical work, manufacturing and the first-in-human protocol will support the US development plan. Use data standards that will convert cleanly to a submission format. Keep a trial master file that would satisfy an inspector. The sponsors who struggle are those who treated the first study as a separate project rather than the first chapter of a US program.
When does staying in the US make more sense?
When the target population is mainly in the US, when early US investigator relationships matter for later phases, when the product has complex logistics that are hard to manage abroad, or when investors or partners value an early IND. Sometimes the time saved abroad is lost later in bridging work, extra regulatory interactions or rework of documentation.
How should a small sponsor decide?
Compare realistic timelines and total costs, including hidden ones, for at least two options. Weigh data acceptability, the plan for later phases, available oversight capacity and the value of any incentives after advisory costs. Then decide deliberately, and write down why. A board or partner will ask.
Keep reading: What US Biotechs Should Know About the EU Clinical Trials Regulation
